InvestorsHub Logo
Followers 85
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: Protector post# 243653

Wednesday, 11/25/2015 6:53:45 AM

Wednesday, November 25, 2015 6:53:45 AM

Post# of 346375

Some will point to outstanding shares (222Mil) and say that those PPS jumps totally depend on them. Nothing is less true, they are only ONE element of it and its impact is therefore limited. The number of shares that cannot SUDDENLY be sold such as those connected to employees and BoD (for instance options that need to be first exercised), the number of shares on shelves of II/Funds that will not come into the liquidity immediately (about 30Mil but that will go up), and the greediness of the retailers (the longer they hold the higher the price will go because there are no real sellers and the MM ups the price to loosen shares because everybody has his price at some point - the Qualcom effect), and the greediness of shorters that will short the peeks but will have to buy back, will all play an important role.

However the MOST IMPORTANT FACTOR will be the Bavituximab potential...
..
..



CP, I would have to admit that when I first heard the words that PPHM can't go up like other stocks because of the 220M abouts outstanding shares I didn't agree and just a glimpse of your post above explains exactly why.

All I can say is "if" so much attention was paid to Peregrine all these years to suppress prices and try to steer them off the road, what is the true amount of outstanding shares that are locked up longterm till a certain price is met? I don't know exactly...

but for example, if 125 Million shares are locked up tight and are not even thinking of selling or being sold till certain prices are met..... then we can actually see that the OS here is actually much lower and closer to 100M

I could be wrong, hell.... maybe 175M shares are in smart hands and locked up for a very long time

Its this case that can truly make this one of the great runs of all times in biotech..

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News